Cargando…
New biologics in the management of Crohn’s disease: focus on certolizumab pegol
Crohn’s disease (CD) is a chronic inflammatory condition involving the gastrointestinal tract characterized by recurrent exacerbations and remission. The disease frequently occurs in the lower part of the small bowel, but can affect any part of the digestive tract, from the mouth to the anus. The tr...
Autores principales: | Colombo, Elisabetta, Bossa, Fabrizio, Latiano, Anna, Palmieri, Orazio, Andriulli, Angelo, Annese, Vito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108632/ https://www.ncbi.nlm.nih.gov/pubmed/21694828 |
Ejemplares similares
-
Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012) -
Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
por: Dinesen, Lotte, et al.
Publicado: (2007) -
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015) -
Functional Implications of MicroRNAs in Crohn’s Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling
por: Palmieri, Orazio, et al.
Publicado: (2017) -
Addendum: Palmieri, O. et al. Functional Implications of MicroRNAs in Crohn’s Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. Int. J. Mol. Sci. 2017, 18, 1580
por: Palmieri, Orazio, et al.
Publicado: (2017)